Aprepitant for Erlotinib-Induced Pruritus

Abstract

To the Editor: In a letter to the editor, Levêque (Oct. 21 issue)(1) comments on a study by Vincenzi et al. (July 22 issue)(2) regarding the off-label use of the antiemetic agent aprepitant for the treatment of pruritus in patients with cancer who are receiving erlotinib. Erlotinib is a small-molecule anticancer drug that targets the epidermal growth factor receptor (EGFR). Rash and pruritus are common adverse effects of EGFR inhibitors and may lead to dose reduction or therapy discontinuation. Mediators that are released from activated dermal mast cells often initiate and amplify pruritus. The neuropeptide substance P represents a prominent ...